Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
186
-
Total 13F shares, excl. options
-
73.7M
-
Shares change
-
+6.05M
-
Total reported value, excl. options
-
$1.36B
-
Value change
-
+$101M
-
Put/Call ratio
-
0.35
-
Number of buys
-
108
-
Number of sells
-
-71
-
Price
-
$18.46
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2022
229 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2022.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 186 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.7M shares
of 105M outstanding shares and own 70.46% of the company stock.
Largest 10 shareholders include Capital World Investors (9.48M shares), BlackRock Inc. (7.07M shares), Palo Alto Investors LP (5.28M shares), JPMORGAN CHASE & CO (5.01M shares), Polar Capital Holdings Plc (4.85M shares), VANGUARD GROUP INC (4.5M shares), FRANKLIN RESOURCES INC (2.38M shares), STATE STREET CORP (2.05M shares), JENNISON ASSOCIATES LLC (2.03M shares), and FMR LLC (1.81M shares).
This table shows the top 186 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.